The net profit of 94 pharmaceutical companies has increased, and these pharmaceutical companies have increased significantly

 Recently, listed pharmaceutical companies have released their 2021 performance reports
.
According to statistics, as of March 2, a total of 126 A-share biopharmaceutical companies have released relevant data, and 94 of them have increased their net profit compared with the same period of the previous year
.
Among them, Zhendong Pharmaceutical, Wantai Bio, Oriental Bio, WuXi AppTec and other pharmaceutical companies have increased their net profits by a large margin
.
Zhendong Pharmaceutical According to the 2021 annual performance report released by Zhendong Pharmaceutical recently, the total operating income of vibration pharmaceutical in 2021 will be 5,092,538,429.
47 yuan, a year-on-year increase of 5.
05%; the net profit attributable to shareholders of the listed company is 2,629,102,780.
81 yuan, a year-on-year increase of 903.
37%
.
Zhendong Pharmaceutical's main business is the research and development, production and sales of vitamins, mineral preparations, traditional Chinese medicines, innovative drugs and other products
.
According to the announcement, Zhendong Pharmaceutical’s operating profit, total profit, and net profit attributable to shareholders of listed companies increased by 856.
00%, 864.
63%, and 903.
37% year-on-year, respectively, mainly due to the sale of Landi Pharmaceuticals
.
According to the 2021 annual performance bulletin released by Wantai Bio recently, Wantai Bio will achieve an operating income of 5.
75 billion yuan in 2021, a year-on-year increase of 144.
25%; a total profit of 2.
321 billion yuan, a year-on-year increase of 203.
59%; attributable to listing The net profit of the company's shareholders was 2.
016 billion yuan, a year-on-year increase of 197.
83%; the net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 1.
940 billion yuan, a year-on-year increase of 214.
48%
.
According to the announcement, the main factors affecting Wantai's business performance are that the company's bivalent cervical cancer vaccine continues to maintain a boom in production and sales, and its revenue and profits increase.
Due to the substantial increase in overseas testing demand, the company's raw material sales and overseas testing reagent export revenue has achieved rapid growth
.
According to the performance report released by Oriental Bio recently, the operating income in 2021 will be 10.
032 billion yuan, a year-on-year increase of 207.
22%; the net profit will be 4.
777 billion yuan, a year-on-year increase of 184.
80%. .
Regarding the performance growth, Orient Bio said that in 2021, the company's virus antigen rapid detection reagents (including home self-test) will continue to be invested in the epidemic prevention business, the sales performance of the products in the European market will continue to increase significantly, and the business of routine diagnostic reagents and diagnostic instruments will maintain stable development.
, prompting a substantial increase in operating performance in 2021
.
According to the recent performance report released by WuXi AppTec, in 2021, WuXi AppTec achieved operating income of 22.
902 billion yuan, a year-on-year increase of 38.
5%; net profit attributable to shareholders of listed companies was 5.
097 billion yuan, a year-on-year increase of 72.
19%
.
WuXi PharmaTech said that the strong demand for orders in the chemical business segment will promote the accelerated growth of sales revenue in 2021
.
The company expects that the revenue growth rate of the chemical business segment in 2022 will nearly double compared to the revenue growth rate in 2021
.
In 2021, the testing business achieved revenue of about 4.
525 billion yuan, a year-on-year increase of 38.
03%
.
Among them, laboratory analysis and testing services revenue increased by 38.
93% year-on-year, and clinical CRO and SMO revenue increased by approximately 36.
2% year-on-year
.
Zhifei Biology According to the 2021 performance report recently disclosed by Zhifei Biology, in 2021, Zhifei Biology achieved revenue of 30.
64 billion yuan, a year-on-year increase of 101.
68%; net profit was 10.
2 billion yuan, a year-on-year increase of 208.
88%
.
Zhifei Bio said that the company continued to focus on business development goals, increased investment in research and development, and introduced new products.
The sales of independent products and agency products continued to increase steadily.
The company's main business income, net profit and other important financial indicators were higher than in 2020.
larger growth
.
Pien Tze Huang According to the recent performance report released by Pien Tze Huang, in 2021, Pien Tze Huang achieved a total operating income of 8,025,845,400 yuan, a year-on-year increase of 23.
27%; the net profit attributable to shareholders of the listed company was 2,432,975,300 yuan, a year-on-year increase of 45.
55%
.
During the reporting period, Pien Tze Huang expanded its marketing channels and added online Pien Tze Huang Pharmacy Tmall flagship store and Pien Tze Huang Pharmacy Jingdong flagship store, which increased the company's profits. .
According to the 2021 performance report released by Rejing Biology recently, Rejing Bio will realize a revenue of 5.
372 billion yuan in 2021, a year-on-year increase of 946.
14%; the net profit attributable to the owner of the parent company is 2.
193 billion yuan, a year-on-year increase of 1856.
81.
%
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.